74 results
Keyword ripretinib Remove keyword
-
List item
Orphan designation: Olverembatinib for: Treatment of chronic myeloid leukaemia
Date of designation: 12/11/2021, Positive, Last updated: 15/06/2022 -
List item
Orphan designation: Adeno-associated viral vector serotype 9 containing the human SURF1 gene for: Treatment of Leigh syndrome
Date of designation: 12/11/2021, Positive, Last updated: 15/06/2022 -
List item
Orphan designation: Glofitamab for: Treatment of diffuse large B-cell lymphoma
Date of designation: 15/10/2021, Positive, Last updated: 20/01/2022 -
List item
Orphan designation: Human IgG1 monoclonal antibody against sortilin for: Treatment of frontotemporal dementia
Date of designation: 15/10/2021, Positive, Last updated: 20/01/2022 -
List item
Orphan designation: Devimistat for: Treatment of Burkitt's lymphoma
Date of designation: 15/10/2021, Positive, Last updated: 20/01/2022 -
List item
Orphan designation: Batiraxcept for: Treatment of ovarian cancer
Date of designation: 15/10/2021, Positive, Last updated: 20/01/2022 -
List item
Orphan designation: Humanised IgG1 monoclonal antibody against SEZ6 linked to N-acetyl-calicheamicin for: Treatment of small cell lung cancer
Date of designation: 15/10/2021, Positive, Last updated: 20/01/2022 -
List item
Orphan designation: Ganaxolone for: Treatment of tuberous sclerosis
Date of designation: 15/10/2021, Positive, Last updated: 20/01/2022 -
List item
Orphan designation: Adeno-associated viral vector serotype 5 expressing the human Cone-Rod Homeobox gene for: Treatment of cone-rod dystrophy
Date of designation: 15/10/2021, Positive, Last updated: 21/01/2022 -
List item
Orphan designation: Allogeneic umbilical cord mesenchymal cells-derived extracellular vesicles for: Prevention of bronchopulmonary dysplasia
Date of designation: 15/10/2021, Positive, Last updated: 21/01/2022 -
List item
Orphan designation: Selinexor for: Treatment of glioma
Date of designation: 15/10/2021, Positive, Last updated: 21/01/2022 -
List item
Orphan designation: Encaleret sulfate for: Treatment of hypoparathyroidism
Date of designation: 15/10/2021, Positive, Last updated: 21/01/2022 -
List item
Orphan designation: Idursulfase beta for: Treatment of mucopolysaccharidosis type II (Hunter's syndrome)
Date of designation: 15/10/2021, Positive, Last updated: 21/01/2022 -
List item
Orphan designation: Psilocybine for: Treatment of fragile X syndrome
Date of designation: 15/10/2021, Positive, Last updated: 21/01/2022 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 28 November - 1 December 2022
European Medicines Agency, Amsterdam, the Netherlands, from 28/11/2022 to 01/12/2022, Last updated: 03/04/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 23-26 January 2023
European Medicines Agency, Amsterdam, the Netherlands, from 23/01/2023 to 26/01/2023, Last updated: 14/04/2023 -
List item
List of medicines under additional monitoring (updated)
Last updated: 30/05/2023 -
List item
Medicines for human use under evaluation
Last updated: 27/09/2022 -
List item
CHMP: Agendas, minutes and highlights (updated)
Last updated: 31/05/2023 -
List item
Pharmacovigilance Risk Assessment Committee (PRAC): 29 August - 1 September 2022
European Medicines Agency, Amsterdam, the Netherlands, from 29/08/2022 to 01/09/2022, Last updated: 02/09/2022 -
List item
Committee for Orphan Medicinal Products (COMP): 5-7 October 2021
European Medicines Agency, Amsterdam, the Netherlands, from 05/10/2021 to 07/10/2021, Last updated: 14/12/2021 -
List item
Newsletters (updated)
Last updated: 30/05/2023 -
List item
PRAC: Agendas, minutes and highlights (updated)
Last updated: 17/05/2023 -
List item
Committee for Medicinal Products for Human Use (CHMP): 21-24 March 2022
European Medicines Agency, Amsterdam, the Netherlands, from 21/03/2022 to 24/03/2022, Last updated: 12/08/2022 -
List item
COMP: Agendas, minutes and meeting reports (updated)
Last updated: 11/05/2023